SLV 301

Drug Profile

SLV 301

Latest Information Update: 15 Oct 2002

Price : $50

At a glance

  • Originator Solvay
  • Class
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 15 Oct 2002 Discontinued - Preclinical for Schizophrenia in Netherlands (unspecified route)
  • 08 Dec 2000 New profile
  • 08 Dec 2000 Preclinical development for Schizophrenia in Netherlands (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top